The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase

• Published in: Journal of clinical pharmacology 2006-01, Vol.46 (1), p.88-102
• Main Authors: Khosravan, Reza, Grabowski, Brian A., Mayer, Michael D., Wu, Jing-Tao, Joseph-Ridge, Nancy, Vernillet, Laurent
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adult; Biotransformation; Care and treatment; Drug Administration Schedule; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - pharmacokinetics; Febuxostat; Female; Gout; hepatic impairment; Humans; Liver Diseases - metabolism; Male; Middle Aged; pharmacodynamics; pharmacokinetics; Thiazoles - administration & dosage; Thiazoles - pharmacokinetics; Thrombolytic drugs; xanthine oxidase; Xanthine Oxidase - antagonists & inhibitors
• ISSN: 0091-2700; 1552-4604
• DOI: 10.1177/0091270005282634

To assess the effect of hepatic impairment on the pharmacokinetics, pharmacodynamics, and safety of febuxostat at steady state, multiple once‐daily 80‐mg oral doses of febuxostat were administered to subjects with normal hepatic function and to subjects with mild or moderate hepatic impairment. There were no statistically significant differences in the plasma pharmacokinetic parameters for unbound febuxostat and its active metabolites between subjects with mild or moderate hepatic impairment and those with normal hepatic function. The percentage decrease in serum uric acid appeared to be lower in hepatic impairment groups (49% [mild] and 48% [moderate]) as compared to the normal hepatic group (62%). This lower percentage decrease was minimal and not considered clinically significant. Febuxostat 80 mg once daily appears to be generally safe and well tolerated in mildly and moderately impaired hepatic function groups, and dose adjustment is not required in subjects with mild to moderate hepatic impairment.